Cargando…

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease

Cushing Disease (CD), caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas, leads to excess production of adrenal-derived cortisol. Current medical treatments for CD include adrenal steroidogenesis inhibitors (Ketoconazole, Metyrapone), the somatostatin receptor ligand Pasireoti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Dongyun, Damoisseaux, Robert, Heaney, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550912/ http://dx.doi.org/10.1210/js.2019-MON-461

Ejemplares similares

PMON149 Identification of TR4 Modulators for Treatment of Cushing Disease.
por: Zhang, Dongyun, et al.
Publicado: (2022)

MON-466 Transcriptome Dynamics of in vitro Human Pituitary Tumor Primary Culture
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-321 AgRP and Food Cravings Decrease with Treatment of Cushing’s Disease
por: Haseltine, Katherine N, et al.
Publicado: (2020)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

MON-405 Cushing's Disease: An Oligosymptomatic Patient with ACTH-Secreting Pituitary Macroadenoma
por: Manrique Franco, Katty, et al.
Publicado: (2019)

MON-404 Reversible Dilated Cardiomyopathy in a Severe Case of Cushing’s Disease
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients
por: Pereira, Ana Julia Garcia, et al.
Publicado: (2020)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

SUN-461 Predictors of Early and Late Hyponatremia after Pituitary Surgery
por: Cooper, Odelia, et al.
Publicado: (2019)

MON-408 Development of Rapidly Progressive Cushing's Disease Following Pituitary Apoplexy Several Years Prior
por: Ortegon Zambrano, Pilar, et al.
Publicado: (2019)

MON-411 Psychological Disturbance And Weight Gain; Early Identification Of Cushing’S Disease In A Teenage Patient.
por: Hasan, Sana
Publicado: (2019)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease
por: Shen, Angeline, et al.
Publicado: (2019)

MON-LB58 The Use of 11C Methionine PET CT In Localization of ACTH Dependent Cushing’s Disease
por: ElEbrashy, Shady Ibrahim, et al.
Publicado: (2020)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

MON-410 Ectopic ACTH- Secreting Tumor Causing Rapidly Progressive Cushing’s Syndrome Remains an Elusive Localization Diagnosis
por: Anaya Noubleau, Axa, et al.
Publicado: (2019)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

MON-444 Defining Remission In Cushing Syndrome After Tumor Resection In Cases Of Non-suppressed Postoperative Serum Cortisol Levels
por: McGlotten, Raven, et al.
Publicado: (2019)

MON-LB51 Stimulation for Bilateral Inferior Petrosal Sinus Sampling May Be Unnecessary for Diagnosis of ACTH Dependent Cushing Syndrome
por: Builes-barrera, Carlos Alfonso, et al.
Publicado: (2020)

MON-329 Diagnostic Utility of Overnight High Dose Dexamethasone Suppression Test for Differentiating the Etiology of ACTH Dependent Cushing’s Syndrome
por: Yadav, Subhash B, et al.
Publicado: (2020)

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease
por: Youssef, Nancy, et al.
Publicado: (2019)

MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI
por: Martel, Luciana, et al.
Publicado: (2019)

MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

SAT-461 Long-Term Effects of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (Hit-Endo)
por: Boekhoff, Svenja, et al.
Publicado: (2019)

OR06-03 Serotonin Regulates Corticotroph Tumor Cell Proliferation and ACTH Secretion
por: Zhang, Dongyun, et al.
Publicado: (2020)

PMON157 Evidence For Locally Produced Cortisol in Pituitary Tissue
por: Tsai, Karen, et al.
Publicado: (2022)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

SAT-248 Cushing’s Disease with Two ACTH-Producing Pituitary Tumors
por: Mathai, Christine, et al.
Publicado: (2020)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gu0v9hf8io71nni7ablosd86bj